Furthermore, there was a significant difference in the levels of EGR1 and VEGF in OHSS patients treated with cetrorelix, a GnRH antagonist, and untreated OHSS patients, with cetrorelix reducing the incidence of moderate and severe OHSS45. Here, EGR1 is linked to ovarian hyperstimulation syndrome.